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Abstract
Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of 
transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic 
animals of the present invention are produced by introducing into developing embryos DNA that encodes 
Factor IX, such that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature 
animal. Particularly efficient expression was accomplished using a chimeric construct comprising a 
mammary gland specific promoter, Factor IX cDNA that lacked the complete or any portion of the 5'-
untranslated and 3'-untranslated region, which is substituted with a 5'- and 3'-end of the mouse whey acidic 
protein gene. In vitro cell cultures of cells explanted from the transgenic mammal of the invention and 
methods of producing Factor IX from such said culture and methods of treating hemophilia B are also 
described. 
Inventors: Velander; William H. (Blacksburg, VA); Drohan; William N. (Springfield, VA); 
Lubon; Henryk (Rockville, MD); Johnson; John L. (late of Blacksburg, VA) 
Assignee: American Red Cross (Rockville, MD); Virginia Tech Intellectual Properties, Inc.
(Blacksburg, VA) 
Appl. No.: 367087
Filed: September 15, 1999
PCT Filed: February 13, 1998 
PCT NO: PCT/US98/02638 
371 Date: March 1, 2000 
102(e) Date: March 1, 2000 
PCT PUB.NO.: WO98/35689
PCT PUB. Date: August 20, 1998
Current U.S. Class: 800/14; 435/69.6; 435/325; 800/7; 800/15; 800/16; 800/17; 
800/18 
Intern'l Class: A01K 067/027
Field of Search: 800/7,14,15,16,17,18 435/325,69.6 
References Cited [Referenced By]
U.S. Patent Documents
4786726 Nov., 1988 Smith. 
4873316 Oct., 1989 Meade et al. 
5171569 Dec., 1992 Anson et al. 
5322775 Jun., 1994 Clark et al. 
5366894 Nov., 1994 Clark et al. 
5476995 Dec., 1995 Clark et al. 
5589604 Dec., 1996 Drohan et al. 
5831141 Nov., 1998 Lubon et al. 800/2. 
Foreign Patent Documents
0 791 652 Aug., 1997 EP. 
0 274 489 Oct., 1997 EP. 
0 396 699 Oct., 1997 EP. 
90/05188 May., 1990 WO. 
91/08216 Jun., 1991 WO. 
94/05796 Mar., 1994 WO. 
95/30000 Nov., 1995 WO. 
Other References
Clark et al (1989) Bio/Technology 7, 487-492.* 
Velander et al (1992) Proc. Natl. Acad. Sci. 89, 12003-12007.* 
Drohan et al (1994) Transgenic Res. 3, 355-364.* 
Anson et al (1985) Nature 315, 683-685.* 
Yull et al (1995) Proced. Natl. Acad. Sci. 92, 10899-10903. 
Primary Examiner: Crouch; Deborah 
Attorney, Agent or Firm: Foley & Lardner 
Parent Case Text
This application claims benefit of U.S. Provisional Application No. 60/037,145, filed Feb. 14, 1997. 
Claims
What is claimed is: 
1. A non-human transgenic mammal containing an exogenous DNA molecule that is stably integrated in its 
genome, wherein said exogenous DNA molecule comprises: 
(a) 5' regulatory sequences of a mammary gland-specific gene including a promoter; 
(b) a Factor IX-encoding DNA sequence that encodes a signal sequence, a Factor IX pro-sequence, and a 
Factor IX sequence in a 5' to 3' direction, wherein said signal sequence is effective in directing the secretion 
of said Factor IX into the milk of said transgenic mammal and wherein said Factor IX sequence lacks the 
complete 5'-untranslated and 3'-untranslated regions of the Factor IX gene; and 
(c) 3' regulatory sequences from a mammary gland-specific gene or 3' regulatory sequences active in a 
mammary gland, 
wherein said 5' and said 3' regulatory sequences are operatively linked to said Factor IX-encoding DNA 
sequence, and wherein said promoter is selected from the group consisting of whey acidic protein (WAP) 
promoter, .alpha.-casein promoter, .beta.-casein promoter, kappa-casein promoter, .alpha.-lactalbumin 
promoter and .beta.-lactoglobulin promoter. 
2. The non-human transgenic mammal of claim 1, wherein said rodent WAP promoter is the 2.6 kb EcoRI-
KpnI promoter of the mouse WAP gene. 
3. The non-human transgenic mammal of claim 1, wherein said rodent WAP promoter is the 4.1 kb NotI-
KpnI promoter or the 4.2 kb Sau3A-KpnI WAP promoter of the mouse WAP gene. 
4. The non-human transgenic mammal of claim 1, wherein said Factor IX-encoding DNA molecule further 
comprises a 5'-untranslated region that is not the 5'-untranslated region of the Factor IX gene. 
5. The non-human transgenic mammal of claim 4, wherein said 5'-untranslated region is the 5'-untranslated 
region of the mouse WAP gene. 
6. The non-human transgenic mammal of claim 1, wherein said Factor IX-encoding DNA molecule further 
comprises a 3'-untranslated region that is not the 3'-untranslated region of the Factor IX gene. 
7. The non-human transgenic mammal of claim 6, wherein said 3'-untranslated region is the 3'-untranslated 
region of the mouse WAP gene. 
8. The non-human transgenic mammal of claim 1, wherein said Factor IX-encoding DNA molecule further 
comprises a 5'-untranslated region located 5' from said signal sequence DNA, and a 3'-untranslated region 
located 3' from said Factor IX sequence. 
9. The non-human transgenic mammal of claim 1, wherein said Factor IX is biologically active human 
Factor IX. 
10. The non-human transgenic mammal of claim 1, wherein said transgenic mammal is selected from the 
group consisting of mice, rats, rabbits, pigs, sheep, goats and cows. 
11. The non-human transgenic mammal of claim 9, wherein said transgenic mammal is a pig and secretes 
from 100 to 220 .mu.g of active human Factor IX per milliliter of milk. 
12. The non-human transgenic mammal of claim 11, wherein said transgenic mammal secretes from about 
100 to about 185 .mu.g of active human Factor IX per milliliter milk. 
13. The non-human transgenic mammal of claim 12, wherein said transgenic mammal secretes from about 
100 to about 170 .mu.g of active human Factor IX per milliliter milk. 
14. The non-human transgenic mammal of claim 11, wherein said transgenic mammal secretes from about 
135 to about 220 .mu.g of active human Factor IX per milliliter milk. 
15. The non-human transgenic mammal of claim 14, wherein said transgenic mammal secretes from about 
145 to about 220 .mu.g of active human Factor IX per milliliter milk. 
16. The non-human transgenic mammal of claim 9, wherein said active human Factor IX, when purified 
from the milk of said transgenic mammal, wherein said transgenic mammal is a pig, has a specific activity 
that is at least about 5-200% greater than the specific activity of human Factor IX isolated from human 
plasma, as determined by an activated partial thromboplastin clotting time assay coagulation assay. 
17. The non-human transgenic mammal of claim 16, wherein said active human Factor IX purified from the 
milk of said transgenic mammal has a specific activity that is at least about 10-100% greater than the 
specific activity of human Factor IX isolated from human plasma. 
18. The non-human transgenic mammal of claim 16, wherein said active human Factor IX purified from the 
milk of said transgenic mammal has a specific activity that is at least about 15-50% greater than the specific 
activity of human Factor IX isolated from human plasma. 
19. The non-human transgenic mammal of claim 16, wherein said active human Factor IX purified from the 
milk of said transgenic pig has a specific activity that is at least about 15-46% greater than the specific 
activity of human Factor IX isolated from human plasma. 
20. The non-human transgenic mammal of claim 1, wherein said WAP promoter is a rodent WAP promoter. 
21. The process of claim 20, wherein said WAP promoter is a rodent WAP promoter. 
22. A process for producing Factor IX, comprising: 
(a) providing a non-human transgenic mammal that has integrated into its genome an exogenous DNA 
molecule that comprises: 
(1) 5' regulatory sequences of a mammary gland-specific gene including a promoter; 
(2) a Factor IX-encoding DNA sequence that encodes a signal sequence, a Factor IX pro-sequence, and a 
Factor IX sequence in a 5' to 3' direction, wherein said signal sequence is effective in directing the secretion 
of said Factor IX into the milk of said transgenic mammal and wherein said Factor IX sequence lacks the 
complete 5'- untranslated and 3'-untranslated regions of the Factor IX gene; and 
(3) 3' regulatory sequences from a mammary gland-specific gene or 3' regulatory sequences active in a 
mammary gland, 
wherein said 5' and said 3' regulatory sequences are operatively linked to said Factor IX-encoding DNA 
sequence, and wherein said promoter is selected from the group consisting of whey acidic protein (WAP) 
promoter, .alpha.-casein promoter, .beta.-casein promoter, kappa-casein promoter, .alpha.-lactalbumin 
promoter and .beta.-lactoglobulin promoter; 
(b) allowing said Factor IX-encoding DNA sequence to be expressed and said Factor IX to be secreted into 
the milk of said transgenic mammal; 
(c) collecting said milk from said mammal; and 
(d) isolating said Factor IX from said milk. 
23. The process of claim 21, wherein said rodent WAP promoter is the 2.6 kb EcoRI-KpnI promoter of the 
mouse WAP gene. 
24. The process of claim 21, wherein said rodent WAP promoter is the 4.1 kb NotI-KpnI promoter or the 4.2 
kb Sau3A-KpnI promoter of the mouse WAP gene. 
25. The process of claim 22, wherein said Factor IX-encoding DNA molecule further comprises a 5'-
untranslated region that is not the 5'-untranslated region of the Factor IX gene. 
26. The process of claim 25, wherein said 5'-untranslated region is the 5'-untranslated region of the mouse 
WAP gene. 
27. The process of claim 22, wherein said Factor IX-encoding DNA molecule further comprises a 3'-
untranslated region that is not the 3'-untranslated region of the Factor IX gene. 
28. The process of claim 27, wherein said 3'-untranslated region is the 3'-untranslated region of the mouse 
WAP gene. 
29. The process of claim 22, wherein said Factor IX-encoding DNA molecule further comprises a 5'-
untranslated region located 5' from said signal sequence DNA, and a 3'-untranslated region located 3' from 
said Factor IX sequence. 
30. The process of claim 22, wherein said Factor IX is biologically active human Factor IX. 
31. The process of claim 22, wherein said transgenic mammal is selected from the group consisting of mice, 
rats, rabbits, pigs, sheep, goats and cows. 
32. The process of claim 30, wherein said transgenic mammal is a pig and secretes from 100 to 220 .mu.g of 
active human Factor IX per milliliter milk. 
33. The process of claim 32, wherein said transgenic mammal secretes from about 100 to about 185 .mu.g of 
active human Factor IX per milliliter milk. 
34. The process of claim 33, wherein said transgenic mammal secretes from about 100 to about 170 .mu.g of 
active human Factor IX per milliliter milk. 
35. The process of claim 32, wherein said transgenic mammal secretes from about 135 to about 220 .mu.g of 
active human Factor IX per milliliter milk. 
36. The process of claim 35, wherein said transgenic mammal secretes from about 145 to about 220 .mu.g of 
active human Factor IX per milliliter milk. 
37. The process of claim 30, wherein said active human Factor IX, when purified from the milk of said 
transgenic mammal, wherein said transgenic mammal is a pig, has a specific activity that is at least about 5-
200% greater than the specific activity of human Factor IX isolated from human plasma, as determined by 
an activated partial thromboplastin clotting time assay coagulation assay. 
38. The process of claim 37, wherein said active human Factor IX purified from the milk of said transgenic 
mammal has a specific activity that is at least about 10-100% greater than the specific activity of human 
Factor IX isolated from human plasma. 
39. The process of claim 38, wherein said active human Factor IX purified from the milk of said transgenic 
mammal has a specific activity that is at least about 15-50% greater than the specific activity of human 
Factor IX isolated from human plasma. 
40. The process of claim 39, wherein said active human Factor IX purified from the milk of said transgenic 
pig has a specific activity that is at least about 15-46% greater than the specific activity of human Factor IX 
isolated from human plasma. 
41. Mammary gland cells obtained from the non-human transgenic mammal of claim 1, wherein said cells 
produce said Factor IX. 
42. An in vitro culture of the mammary gland cells of claim 41. 
43. A method of producing Factor IX, said method comprising the step of isolating said Factor IX from the 
cultured mammary gland cells of claim 42. 
Description
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the production of natural and modified forms of Factor IX. In particular, the 
invention relates to a transgenic animal containing, stably incorporated in its genomic DNA, an exogenous 
Factor IX gene that is expressed specifically in mammary tissue, such that Factor IX is secreted into milk 
produced by the animal. In particular, the invention relates to the production of human Factor IX in the milk 
of a transgenic non-human mammal using a DNA molecule that comprises a whey acidic protein promoter 
gene, 5' regulatory sequences containing the promoter, human Factor IX cDNA that lacks at least a portion 
of the complete or any portion of or the complete the 3'-untranslated region of the native human Factor IX 
gene, but contains the 5' and 3-untranslated region of the mouse whey acidic protein. gene. 
2. Background 
Human Factor IX, or "Christmas factor," is encoded by a single-copy gene residing on the X-chromosome at 
q27.1. For a review of Factor IX gene structure and expression, see High et al., "Factor IX," in 
MOLECULAR BASIS OF THROMBOSIS AND HEMOSTASIS, High (ed.), pages 215-237 (Dekker 
1995); Kurachi et al., Thromb. Haemost. 73:333 (1995). The Factor IX gene is at least 34 kilobase (kb) pairs 
in size, and it is composed of eight exons. The major transcription start site of the Factor IX gene in human 
liver is located at about nucleotide-176. The human Factor IX mRNA is composed of 205 bases for the 5' 
untranslated region, 1383 bases for the prepro Factor IX, a stop codon and 1392 bases for the 3' untranslated 
region. 
Factor IX is synthesized as a prepropolypetide chain composed of three domains: a signal peptide of 29 
amino acids, a propeptide of 17 amino acids, which is required for .gamma.-carboxylation of glutamic acid 
residues, and a mature Factor IX protein of 415 amino acid residues. The Factor IX zymogen undergoes 
three types of post-translational modifications before it is secreted into the blood: a vitamin K-dependent 
conversion of glutamic acid residues to carboxyglutamic acids, addition of hydrocarbon chains, and .beta.-
hydroxylation of an aspartic acid. Mature Factor IX protein contains 12 .gamma.-carboxylated glutamic acid 
(Gla) residues. Due to the requirement of vitamin K by .gamma.-carboxylase, Factor IX is one of several 
vitamin K-dependent blood coagulation factors. 
The activation of Factor IX is achieved by a two-step removal of the activation peptide (Ala.sup.146 -
Arg.sup.180) from the molecule. Bajaj et al., "Human factor IX and factor IXa," in METHODS IN 
ENZYMOLOGY (1993). The first cleavage is made at the Arg.sup.145 -Ala.sup.146 site by either Factor 
XIa or Factor VIIa/tissue factor. The second, and rate limiting cleavage is made at Arg.sup.180 -
Val.sup.181. The activation pathways involving Factor XIa and Factor VIIa/tissue factor are both calcium-
dependent. However, the Factor VIIa/tissue factor pathway requires tissue factor that is released from 
damaged endothelial cells. Activated human Factor IX thus exists as a disulfide linked heterodimer of the 
heavy chain and light chain. For full biological activity, human Factor IX must also have the propeptide 
removed and must be fully .gamma.-carboxylated. Kurachi et al., Blood Coagulation and Fibrinolysis 4:953 
(1993). 
Factor IX is the precursor of a serine protease required for blood clotting by the intrinsic clotting pathway. 
Defects in Factor IX synthesis result in hemophilia B (or Christmas disease), an X-linked disorder that 
occurs in about one in 30,000 males. Patients with hemophilia B are treated with Factor IX obtained from 
pooled plasma from normal individuals. Martinowitz et al., Acta Haematol 94(Suppl. 1):35 (1995). Such 
Factor IX preparations, however, may be pyrogenic and may be contaminated with pathogenic agents or 
viruses. Accordingly, it would be advantageous to develop a means to prepare purified Factor IX that did 
not require extraction from human plasma. 
In the past, therapeutic proteins have been produced in E. coli. However, limitations in secretion and post-
translational modification which occur in all living cells has rendered recombinant protein production a 
highly species, tissue and cell specific phenomena. In an example of recombinant FIX expression in 
mammalian cells, the populations of recombinant FIX produced in baby hamster kidney cells are not the 
same protein products as FIX produced in Chinese hamster ovary cells (Busby et al., Nature 316:684-686 
(1985); Kaufman et al., J. Biol. Chem. 261: 9622-9628 (1986)). These proteins have profound differences in 
.gamma.-carboxylation and propeptide removal and these differences have been established as being very 
important in determining biological activity. Most importantly, only less than about 40 milliunits/hr/ml of 
active rFIX were detected in CHO cells even after coexpression of the propeptide cleaving enzyme PACE, 
coexpression of the carboxylase enzyme, and extensive gene amplification with methotrexate in an attempt 
to increase expression level and activity (Wasley et al. J. Biol. Chem. 268: 8458-8465 (1993); Rehemtulla et 
al., Proc. Natl. Acad. Sci. (USA), 90: 4611-4615 (1993)). Researchers concluded that multiple limitations in 
the secretion of active rFIX exist in mammalian cells (Rehemtulla et al., 1993) and that the problem of gene 
transcription was secondary and indeed trivial with respect to post-translational processing of biologically 
active rFIX in mammalian cells. Thus, FIX mRNA splicing is a species specific effect occurring in mice and 
perhaps sheep, but not pigs. Although one might hypothesize that a FIX could be expressed, one could not 
predict with any certainty whether such product would be a clinically acceptable, practical, recombinant 
therapeutic FIX product for a given hemophiliac indication. 
Production of recombinant Factor IX in mammalian cell culture (HepG2, mouse fibroblast, mouse 
hepatoma, rat hepatoma, BHK, CHO cells) repeatedly has been shown to be recalcitrant and cell-system 
specific with respect to intracellular restrictions on secretion and proteolytic processing, post-translational 
modification, expression levels, biological activity, downstream recovery from production media, and 
substantiation of circulation half-life (Busby et al., (1985); de la Salle et al. Nature 316: 268-270 (1985); 
Anson et al., Nature 315: 684-686 (1985); Rehemtulla et al., 1993; Wasley, et al., (1993); Kaufman et al., 
(1986); Jallat et al., EMBO J. 9: 3295-3301 (1990)). Importantly, the aforementioned works concluded that 
nontrivial improvements in these combined criteria are needed if a practical prophylactic FIX therapeutic 
product is to be made available from any recombinant mammalian cell production source. For example, 
attempts to increase the specific activity of rFIX produced by CHO cells by rectifying problems with under-
carboxylation by co-expression of the vitamin K-dependent carboxylase enzyme resulted in no improvement 
in .gamma.-carboxylation or biological activity (Rehemtulla et al., (1993), implying that multiple rate 
limitations in this post-translational modification exist. 
Similar difficulties in the production of significant amounts of biologically active rFIX in the mammary 
epithelial cells of transgenic animals also has been documented in the literature. Although WO-A-90/05188 
and WO-A- 91-08216 predict that production of rFIX should be possible in their production systems, no data 
are presented in WO-A-91-08216, and only very low levels of secreted rFIX (25 ng/ml) with no biological 
activity were reported in transgenic sheep in WO-A 90/05188 and in related publications (Clark et al., 
Bio/Technology 7: 487-4992 (1989)). Higher expression levels have recently been reported in the milk of 
sheep (5 .mu.g/ml), but again, the product had no biological activity (Colman, IBC Third International 
Symposium on Exploiting Transgenic Technology for Commercial Development, San Diego, Calif. (1995)). 
This demonstrates that the polypeptides produced in WO-A-90/05188, Clark et al. (1989), and Colman 
(1995) were a different species than native human FIX with dissimilar biological activity to human FIX, and 
could never be used for therapeutic purposes. Work by Clark et al. (1992) stated that problems in synthesis 
of rFIX in the mammary gland of transgenic mice was the result of aberrant splicing of the rFIX mRNA in 
the 3' untranslated region. Correction of the aberrant splicing in transgenic mice has been demonstrated 
(Yull et al. Proc. Natl. Acad. Sci. USA 92: 10899-10903 (1995); Clark, et al. (1989), WO 95/30000)),
resulting in higher expression levels (up to 61 .mu.g/ml) with about 40% biological active material. 
However, this aberrant splicing phenomenon appears to be species- and tissue-specific in the mouse 
mammary gland; other reports with the 3' UTR sequences in CHO cell lines and in the liver of transgenic 
mice specifically show no evidence of aberrant splicing (Kaufman et al., (1986); Jallat et al., (1990)). In 
addition, no evidence was reported for aberrant mRNA splicing of FIX transcripts with 3' UTR sequences in 
a human hepatoma cell line (de la Salle et al., (1985)), a mouse fibroblast cell line (de la Salle et al., (1985)), 
a rat hepatoma cell line (Anson et al., 1985)), or a BHK cell line (Busby et al., (1985)). No data are 
presented to justify the prediction that the altered transgene of WO95/30000 will necessarily improve the 
secretion and biological activity of rFIX in the milk of transgenic livestock or any other cell line. Therefore 
the claims presented in WO 95/30000 are purely speculative and are limited to the mammary gland of 
transgenic mice. 
The stability of the rFIX product in the milk of transgenic livestock during upstream and downstream 
processing is a critical issue for the production of a practical therapeutic. Data presented in Clark et al. 
(1989) showed that Clark's method of downstream recovery of what little rFIX was in the milk of their 
transgenic sheep was not reproducible: in one of the preparations, a significant amount of rFIX was 
proteolytically activated. The infusion of activated FIX (FIXa) into a patient is fatal (Kingdon et al., 
Thrombosis, Diathes. Haemorrh. (Stuttg.) 33: 617 (1975)). FIX can be activated by FXI and/or FVIIa/Tissue 
factor complex in the presence of calcium and phospholipids (Kurachi et al., Blood Coagulation and 
Fibrinolysis 4: 953-974 (1993)). Milk is a medium containing calcium and phospholipid surfaces. In 
addition, there is extensively conserved homology between mammalian blood coagulation factors, 
especially between porcine FXI and human FXI (Mashiko and Takahashi, Biol. Chem. Hoppe-Seyler 375: 
481-484 (1994)). Detectable levels of porcine FVII(a) and FXI(a) in the milk of nontransgenic pigs, and 
elevated levels of FVII(a) and FXI(a) in the milk of a pig with mastitic milk have been measured. Thus, one 
could predict that the recovery of a useful unactivated rFIX produced in the milk of transgenic livestock will 
be very sensitive to the health of the mammary gland (i.e., no subclinical or clinical mastitis), to the milking 
procedure (i.e., no tissue damage), to pretreatment of the milk immediately after collection, to storage of the 
milk before processing, and to the purification and formulation process itself. One would also predict that 
the undesirable in vivo activation of rFIX also can be minimized by the coexpression of inhibitors to 
FVIIa/TF such as the Tissue Factor Pathway Inhibitor (TFPI) protein, also called LACI, or the hybrid 
protein FX-LACI which is also a known inhibitor to FVIIa/TF. Although specific inhibitors of FXIa have 
not been identified, a similar approach can be made for neutralizing FXIa activation by coexpression of 
analogues of polypeptide substrates of FXIa similar to those that are commercially available for amidolytic 
assays. Yet another strategy may be to overexpress rFIX at very high levels (>1 g/l milk) such that the FIX 
activating enzyme is extremely limiting. Otherwise, steps must he taken immediately after milk collection to 
minimize activation. These include, but are not limited to, chelation of calcium (e.g., addition of EDTA), 
phospholipid removal, adjustment of pH, storage in ultra-low freezers, controlled thawing procedures, 
addition of protease inhibitors, and purification procedures that maintain minimal activation conduciveness. 
If activated rFIX still persists in the purified product, removal can be facilitated by lectin 
chromatography(N-linked carbohydrate moieties exist only in the activation peptide), immunoaffinity 
chromatography using a Mab directed to the activation peptide, or by metal ion induced precipitation 
techniques that can select for the differences in molecular stability of unactivated vs. activated FIX. Because 
of these inherent difficulties in production of active FIX at sufficiently high levels in mammalian cells and 
transgenic livestock, gene therapy has been cited as perhaps a more practical way of achieving a 
prophylactic therapeutic rather than recombinant technology (Kurachi et al., (1993); Kay et al., Proc. Natl. 
Acad. Sci. USA 91: 2353-2357 (1994)); Fallaux et al., Thromb-Haemost. 74: 266-73 (1995)). This is 
certainly a profound reality because it specifically teaches a product suitable for FIX prophylaxis has not yet 
been found using recombinant production in mammalian cells, even those that have been shown to express 
active FIX, albeit at low levels. The best recombinant FIX cell production system made from CHO cells is 
produced at low secretion levels (Rehemtulla et al., (1993)) and is in fact not suitable for prophylaxis. 
Furthermore, the data have shown that the homologous plasma proteins FIX and protein C all have very 
different, cell-specific restrictions on post-translational processing, proteolytic processing, and secretion 
which preclude on a protein-specific basis the predictability of high expression levels, biological activity, 
downstream recovery from production media, and predictable circulation half-life (Grinnell et al., "Native 
and Modified recombinant human protein C: function, secretion, and postranslational modifications," In 
Protein C and Related Anticoagulants, eds. D. F. Bruley and Drohan 29-63, Gulf Publishing Co., Houston, 
Tex. (1990); Yan et al., Trends in Biochem. Sci. (1989); Busby et al., (1985)). 
Therefore, a need still exists for a means to obtain significant amounts of purified Factor IX from a source 
other than human plasma. A need also exists for a practical means for producing in mammalian cells rFIX, 
which is suitable as a treatment for hemophilia B. 
SUMMARY OF THE INVENTION 
Accordingly, it is an object of the present invention to provide a method for producing a transgenic animal 
that secretes biologically human active Factor IX into its milk. 
It is a further object of this invention to provide a transgenic animal that produces at least 100 .mu.g of 
human Factor IX per milliliter of milk. 
These and other objects are achieved, in accordance with one embodiment of the present invention by the 
provision of a transgenic non-human mammal containing an exogenous DNA molecule stably integrated in 
its genome. A non-human transgenic mammal containing an exogenous DNA molecule stably integrated in 
its genome, wherein said exogenous DNA molecule comprises: 
(a) 5' regulatory sequences of a mammary gland-specific gene including a promoter; 
(b) a Factor IX-encoding DNA sequence that encodes a signal sequence, a Factor IX pro-sequence and a 
Factor IX sequence in a 5'to 3' direction, wherein said signal sequence is effective in directing the secretion 
of said Factor IX into the milk of said transgenic mammal and wherein said Factor IX sequence lacks at 
least a portion of the complete or the complete 5'-untranslated and 3'-untranslated regions of the Factor IX 
gene.; and 
(c) 3' regulatory sequences from a mammary gland-specific gene or 3' regulatory sequences active in a 
mammary gland; 
wherein said 5' and said 3' regulatory sequences are operatively linked to said Factor IX-encoding DNA 
sequence. 
Mammary gland-specific promoters that are useful in the present invention are selected from the group 
consisting of short whey acidic protein (WAP) promoter, long WAP promoter, short .alpha.-casein 
promoter, short .beta.-casein promoter, short kappa-casein promoter, long .alpha.-casein promoter, long 
.beta.-casein promoter, long kappa-casein promoter, .alpha.-lactalbumin promoter and .beta.-lactoglobulin 
promoter. 
Non-human transgenic mammals which are contemplated by the present invention are selected from the 
group consisting of mice, rats, rabbits, pigs, sheep, goats and cows. 
It is a further object to provide a process for producing Factor IX by providing a non-human transgenic 
mammal having integrated into its genome an exogenous DNA molecule, wherein said exogenous DNA 
molecule comprises: 
(a) providing a non-human transgenic mammal having integrated into its genome an exogenous DNA 
molecule, wherein said exogenous DNA molecule comprises: (1) 5' regulatory sequences of a mammary 
gland-specific gene including a promoter; (2) a Factor IX-encoding DNA sequence that encodes a signal 
sequence, a Factor IX pro-sequence and a Factor IX sequence in a 5' to 3' direction, wherein said signal 
sequence is effective in directing the secretion of said Factor IX into the milk of said transgenic mammal 
and wherein said Factor IX sequence lacks at least a portion of the complete or the complete 5'-untranslated 
and 3'-untranslated regions of the Factor IX gene.; and (3) 3' regulatory sequences from a mammary gland-
specific gene or 3' regulatory sequences active in a mammary gland; wherein said 5' and said 3' regulatory 
sequences are operatively linked to said Factor IX-encoding DNA sequence; 
(b) allowing said DNA sequences encoding said Factor IX to be expressed and said Factor IX to be secreted 
into the milk of said transgenic mammal; 
(c) collecting said milk from said mammal; and 
(d) isolating said Factor IX from said milk. 
It is a further object to provide a method of treating hemophilia B using the Factor IX produced by the 
transgenic mammal, described above. Treating involves administration of the Factor IX of the invention and 
a pharmaceutically acceptable carrier to a hemophilia B patient. 
It is a further object of the invention to provide an in vitro culture of mammary gland cells that produce 
Factor IX. Another object of the invention is to provide a method of treating hemophilia B by implanting 
such Factor IX mammary gland cells into a patient. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A-1D schematically depict the construction of a chimeric Factor IX construct. Specifically, FIG. 1A 
shows the construction of pWAP4. FIG. 1B shows the production of pUCFIX. FIG. 1C shows the 
introduction of human FIX cDNA into pWAP4. FIG. 1D shows the production of pUCWAPFIX. FIX 
cDNA was modified by PCR in order to introduce KpnI sites on the 3' and 5' ends. Using FIX cDNA as a 
template, PCR primers humFIX5'KpnI and humFIX3'KpnI, as shown in Table 1, below, were used to 
produce FIX cDNA with KpnI sites on both ends. Modified cDNA may be easily into a "cassette vector" for 
constructing a chimeric gene. 
FIG. 2 shows the detection of recombinant Factor IX in transgenic pig milk using western blot analysis. 
FIGS. 3A-3C show the production of the pUCWAP6 "cassette vector." Specifically, FIG. 3A shows the 
production of pUCNotI. FIG. 3B shows the production of pUCWAP5 and the production of a fragment that 
contains the pUCNotI vector sequence flanked by mWAP3'UTR. FIG. 3C shows the production of 
pUCWAP6. 
FIG. 4 shows the production of plasmid pUCWAP6FIX. 
DETAILED DESCRIPTION 
1. Overview 
As discussed above, a method for producing significant quantities of Factor IX in transgenic animals has 
been elusive. Yull et al., Proc. Nat'l Acad. Sci. USA 92:10899 (1995), showed that correction of a cryptic 
RNA splice site increases the amount of Factor IX synthesized by transgenic animals. In these studies, one 
transgenic mouse line produced about 27 .mu.g of biologically active Factor IX per milliliter of milk, 
although, Factor IX levels of individual mice of the line varied. Yull et al. speculated that the variation was 
probably due to epigenetic instability. 
In contrast, the studies presented herein show that transgenic pigs can synthesize and secrete high levels 
(100-200 .mu.g/ml milk) of biologically active recombinant human Factor IX in milk. Based on reduced and 
nonreduced SDS PAGE, the majority of the recombinant human Factor IX population appears to be a single 
chain polypeptide having a post-translationally modified structure similar to human Factor IX. The 
recombinant human Factor IX secreted into pig milk is biologically active and is able to initiate clotting in 
Factor IX-deficient human plasma. This is the first reported production of high levels of fully active, 
sufficiently .gamma.-carboxylated, recombinant human Factor IX in the milk of transgenic livestock. 
2. Methods for Producing Transgenic Animals 
Notwithstanding past failures to express recombinant human Factor IX with suitably high activity in several 
different expression systems, the present invention provides methods for obtaining recombinant Factor IX 
characterized by a high percentage of active protein from the milk of transgenic animals. As used herein, the 
term "animal" denotes all mammalian animals except humans. It also includes an individual animal in all 
stages of development, including embryonic and fetal stages. A "transgenic" animal is any animal with cells 
that contain genetic information received, directly or indirectly, by deliberate genetic manipulation at the 
subcellular level, such as by microinjection or infection with recombinant virus. 
The genetic information to be introduced into the animal is preferably foreign to the species of animal to 
which the recipient belongs (i.e., "heterologous"), but the information may also be foreign only to the 
particular individual recipient, or genetic information already possessed by the recipient. In the last case, the 
introduced gene may be differently expressed than is the naturally occurring, or "native," gene. 
The language "germ cell line transgenic animal" refers to a transgenic animal in which foreign DNA has 
been incorporated into a germ line cell, therefore conferring the ability to transfer the information to 
offspring. If such offspring, in fact, possess some or all of that information, then they, too, are transgenic 
animals. 
The transgenic animals of this invention are other than human, including, but not limited to farm animals 
(pigs, goats, sheep, cows, horses, rabbits and the like) rodents (such as mice), and domestic pets (for 
example, cats and dogs). Livestock animals such as pigs, sheep, goats and cows, are particularly preferred. 
Preferably, a transgenic animal of the present invention is produced by introducing into single cell embryos 
appropriate polynucleotides that encode human Factor IX, or fragments or modified products thereof, in a 
manner such that these polynucleotides are stably integrated into the DNA of germ line cells of the mature 
animal, and are inherited in normal Mendelian fashion. 
In accordance with the invention, DNA molecules can be introduced into embryos by a variety of means to 
produce transgenic animals. For instance, totipotent or pluripotent stem cells can be transformed by 
microinjection, calciumphosphate mediated precipitation, liposome fusion, retroviral infection or by other 
means. The transformed cells can then be introduced into embryos and incorporated therein to form 
transgenic animals. In a preferred method, developing embryos can be infected with retroviral vectors and 
transgenic animals can be formed from the infected embryos. In the most preferred method, however, the 
DNA molecules of the invention are injected into embryos, preferably at the single-cell stage, which are 
allowed to develop into mature transgenic animals. However, the present invention is not limited to this-
preferred method but other methods of making transgenic animals can be used as described, for example, in 
Transgenic Animal Generation and Use by L. M. Houdebine, Harwood Academic Press, 1997. Transgenic 
animals also can be generated using methods of nuclear transfer or cloning using embryonic or adult cell 
lines as described for example in Campbell et al., Nature 380: 64-66 (1996) and Wilmut et al., Nature 385: 
810-813 (1997). Further a technique utilizing cytoplasmic injection of DNA can be used as described in 
U.S. Pat. No. 5,523,222. 
Factor IX-producing transgenic animals can be obtained by introducing a chimeric construct comprising 
Factor IX-encoding sequences. An alternative method of producing transgenic animals is to introduce a 
Factor IX chimeric construct with a second construct that may provide higher expression more frequently 
than that observed with the use of Factor IX constructs alone. As described herein, such doubly-transgenic, 
or "bigenic," animals have native WAP genomic sequences that are injected as separate constructs to be 
concatenated in vivo as additional flanking sequences to the target Factor IX cDNA construct. 
Methods for obtaining transgenic animals are well-known. See, for example, Hogan et al., 
MANIPULATING THE MOUSE EMBRYO, (Cold Spring Harbor Press 1986); Krimpenfort et al., 
Bio/Technology 9:88 (1991); Palmiter et al., Cell 41:343 (1985), Kraemer et al., GENETIC 
MANIPULATION OF THE EARLY MAMMALIAN EMBRYO, (Cold Spring Harbor Laboratory Press 
1985); Hammer et al., Nature 315:680 (1985); Wagner et al., U.S. Pat. No. 5,175,385; Krimpenfort et al., 
U.S. Pat. No. 5,175,384, Janne et al., Ann. Med. 24:273 (1992), Brem et al., Chim. Oggi. 11:21 (1993), 
Clark et al., U.S. Pat. No. 5,476,995, hereby incorporated by reference. 
3. Construction of Chimeric Genes 
Suitable Factor IX-encoding DNA used for producing transgenic animals can be obtained using human liver 
tissue as a source for cloning the human Factor IX gene. The DNA coding for Factor IX can be fused, in 
proper reading frame, with appropriate regulatory signals, as described in greater detail below, to produce a 
chimeric construct which is then amplified, for example, by propagation in a bacterial vector, according to 
conventional practice. 
The amplified construct is thereafter excised from the vector and purified for use in microinjection. The 
purification is preferably accomplished by means of high performance liquid chromatography (HPLC), 
which removes contamination of the bacterial vector and from polysaccharides typically present when other 
techniques, such as conventional agarose electroelution, are used. The preferred HPLC method entails 
sorbing the construct onto an anion-exchange HPLC support and selectively eluting the construct from the 
support, preferably with an aqueous sodium chloride solution, thereby to eliminate contamination from the 
vector. Elution also may be effected by other means, such as a pH gradient. 
Alternatively, the excised construct can be purified by ultracentrifugation through an aqueous sucrose or 
sodium chloride gradient, gel electroelution followed by agarose treatment and ethanol precipitation, or low 
pressure chromatography. 
Since it is preferable that the construct have the minimum amount of impurities, more than one cycle of 
HPLC or other purification is advantageous. In particular, the use of HPLC-purified DNA for 
microinjection, as described above, allows for remarkably high transformation frequencies, on the order of 
20% or more, for example, in mice and pigs. 
DNA constructs useful in the present invention provide a DNA sequence encoding Factor IX, preferably 
human Factor IX, operably linked to all the cis-acting signals necessary for mammary tissue specific 
expression of Factor IX, post-translational modification of Factor IX, secretion of Factor IX into milk, and 
full biological activity of Factor IX. Although the present invention preferably entails the use of DNA 
constructs that produce the desired or native human Factor IX per se, the desired protein also may be 
produced as a fusion protein containing another protein. For example, the desired recombinant protein of 
this invention may be produced as part of a larger recombinant protein in order to stabilize the desired 
protein or to make its purification from milk faster and easier. The fusion partners then are separated 
chemically or enzymatically, and the desired protein isolated. 
Methods for obtaining human Factor IX-encoding DNA molecules and nucleotide sequences of human 
Factor IX gene and cDNA are provided, for example, by Kurachi et al., Proc. Nat'l Acad. Sci. USA 79:6461 
(1982), Choo et al., Nature 299:178 (1982), Anson et al., EMBO J. 3:1053 (1984), Brownlee et al., 
international publication No. WO 84/00560, Yull et al., Proc. Nat'l Acad. Sci. USA 92: 10899 (1995), Clark, 
international publication No. WO 95/30000, and Meulien, U.S. Pat. No. 5,521,070 (1996). Human Factor IX 
probes also can be obtained from the American Type Culture Collection, Rockville, Md. (e.g., ATCC Nos. 
61385, 79588, 79602, or 79610). 
Alternatively, Factor IX-encoding DNA molecules may be obtained by synthesizing the genes with 
mutually priming long oligonucleotides. See, for example, Ausubel et al., supra, at pages 8.2.8 to 8.2.13; 
Wosnick et al., Gene 60:115 (1987). Moreover, the polymerase chain reaction can he used to synthesize 
DNA fragments as large as 1.8 kilobases in length. Bambot et al., PCR Methods and Applications 2:266 
(1993). 
Suitable Factor IX-encoding DNA molecules include genomic or complementary DNA molecules that 
encode naturally occurring Factor IX. In a preferred embodiment, DNA molecules encoding human Factor 
IX are employed, including cDNA and genomic DNA molecules. However, the present invention discloses 
that a cDNA based construct as described herein can be successfully used for the expression of human 
Factor IX at commercially useful levels. Particularly a cDNA based construct containing 5' regulatory 
sequences of a mammary gland specific gene including a promoter, a Factor IX-encoding DNA sequence as 
described herein, and 3' regulatory sequences from a mammary gland-specific gene or 3' regulatory 
sequences active in a mammary gland is preferred. Factor IX-encoding DNA molecules from other species 
may also be used, such as the Factor IX encoded by rats, pigs, sheep, cows and chimpanzees. 
It also will be appreciated that the Factor IX cDNA fragment described herein can be modified using 
recombinant DNA techniques to obtain functionally equivalent molecules. For example, 3' or 5' portions of 
the Factor IX gene can be added, or completely deleted, or a few bases at either end may be removed. 
Introns can be removed or added, or portions of one or more introns can be deleted. Additional nucleotide 
sequences can be inserted into them. The sequences of the introns can be altered. Exons can be modified in 
accordance with the discussion of modified Factor IX molecules set forth below. Most modified forms of 
the preferred Factor IX cDNA fragment will not be significantly changed in their ability in transgenic 
animals to engender the production of milk-born Factor IX. In one embodiment, the Factor IX encoding 
portion of the gene lacks the complete 5'-untranslated and 3'-untranslated regions of the native Factor IX 
gene. Thus, these substantially similar fragments will be equivalent in the invention to the particularly 
disclosed Factor IX cDNA fragment. 
A 5'-untranslated region that is not the 5'-untranslated region of the Factor IX gene can be included in the 
present DNA Factor IX constructs, particularly the 5'-untranslated region of the mouse WAP gene. Likewise 
a 3'-untranslated region that is not the 3'-untranslated region of the Factor IX gene, particularly the 3'-
untranslated region of the mouse WAP gene. 
Further, the Factor IX-encoding DNA molecule can also comprise a 5'-untranslated region located 5' from 
the signal sequence DNA, and a 3' -untranslated region located 3' from the Factor IX coding sequence. 
Additional useful modifications of Factor IX include those that alter post-translational modifications, size or 
active site, or that fuse this protein or portions thereof to another protein. Such modifications can be 
introduced into the protein by techniques well known in this art, such as by synthesizing modified genes by 
ligation of overlapping oligonucleotide or introducing mutations into the cloned genes by, for example, 
oligonucleotide-mediated mutagenesis. See, generally, Ausubel et al. (eds.), CURRENT PROTOCOLS IN 
MOLECULAR BIOLOGY, pages 8.0.3-8.5.9 (1990); McPherson (ed.), DIRECTED MUTAGENESIS: A 
PRACTICAL APPROACH, IRL Press (1991). 
The examples described herein demonstrate that a transgenic animal can be produced that synthesizes a 
sufficiently .gamma.-carboxylated, biologically active Factor IX in mammary tissue. Accordingly, the basic 
methods of the present application can be used to obtain transgenic animals that produce other vitamin K-
dependent blood coagulation factors, such as Factor II, Factor VII, Factor X, or the anticoagulation protein, 
Protein S. DNA molecules encoding these proteins can be obtained by standard methods. See, for example, 
Pollak et al., J. Biol. Chem. 271: 1738 (1996), which describes the characterization of the Factor VII gene, 
which is located on chromosome 13 just 2.8 kilobase pairs 5' to the Factor X gene. 
The cis-acting regulatory regions useful in the invention include the promoter that drives expression of the 
Factor IX gene. Promoters particularly useful in the invention are "active" in mammary tissue in that the 
promoters are more active in mammary tissue than in other tissues under physiological conditions where 
milk is synthesized. Most preferred are promoters that are both specific to and efficient in mammary tissue. 
By "efficient" it is meant that the promoters are strong promoters in mammary tissue that can support the 
synthesis of large amounts of protein for secretion into milk. Among such promoters, highly preferred are 
the short and long whey acidic protein (WAP), short and long .alpha., .beta. and kappa casein, .alpha.-
lactalbumin and .beta.-lactoglobulin ("BLG") promoters. 
Promoters may be selected on the basis of the protein compositions of milk from various species. For 
example, the WAP and BLG promoters are particularly useful with transgenic rodents, pigs and sheep. The 
rodent WAP short and long promoters have been used to express the rat WAP gene, the human tissue-type 
plasminogen activator gene and the CD4 gene, while the sheep BLG promoter has been used to express the 
sheep BLG gene, the human alpha-1-antitrypsin gene and the human Factor IX gene. See, for example, 
Paleyanda et al., 1991, above, and Clark et al., TIBTECH 5: 20 (1987). Preferred promoters include the 
rodent casein and WAP promoters, and the casein, .alpha.-lactalbumin and BLG promoters from porcine, 
bovine, equine and ovine (pigs, sheep, goats, cows, horses), rabbits, rodents and domestic pets (dogs and 
cats). The genes for these promoters have been isolated and their nucleotide sequences have been published. 
See, for example, Clark et al. (1987), above, and Henninghausen, Protein Expression and Purification 41: 3 
(1990). 
A useful promoter may be isolated by carrying out conventional restriction endonuclease and subcloning 
steps. A mouse WAP promoter, isolated as a 2.6 kb EcoRI-KpnI fragment immediately 5' to the WAP signal 
sequence, is preferred, although the "long" WAP promoter (the 5' 4.2 kb Sau3A-KpnI promoter of the 
mouse WAP gene, or a fragment thereof) is also suitable for carrying out this invention. The publication of 
Paleyanda et al., Transgenic Research 3: 335 (1994), for example, provides examples of a suitable short 
mouse WAP promoter ("2.5 kb mWAP promoter") and a long mouse WAP promoter ("4.1 kb mWAP 
promoter"). Pages 336-339 of the Paleyanda publication are incorporated by reference. Also see, for 
example, Gordon et al., Bio/Technology 5: 1183 (1987); McKnight et al., "The Whey Acidic Protein," in 
GENES, ONCOGENES, AND HORMONES: ADVANCES IN CELLULAR AND MOLECULAR 
BIOLOGY OF BREAST CANCER, Dickson et al. (eds.), pages 399-412 (Kluwer Academic Publishers 
1991). 
Additional regulatory sequences direct secretion of proteins into milk and/or other body fluids of the 
transgenic animal. In this regard, both homologous and heterologous regulatory sequences are useful in the 
invention. Generally, regulatory sequences known to direct the secretion of milk proteins, such as either 
signal peptides from milk or the nascent target polypeptide, can be used, although signal sequences can also 
be used in accordance with this invention that direct the secretion of expressed proteins into other body 
fluids, particularly blood and urine. Examples of such sequences include the signal peptides of secreted 
coagulation factors including signal peptides of Factor IX, protein C, and tissue-type plasminogen activator. 
Among the useful sequences that regulate transcription, in addition to the promoters discussed above, are 
enhancers, splice signals, transcription termination signals, polyadenylation sites, buffering sequences, RNA 
processing sequences and other sequences which regulate the expression of transgenes. Particularly useful in 
this regard are those sequences that increase the efficiency of the transcription of the genes for Factor IX in 
the mammary gland or other cells of the transgenic animals listed above. Preferred are transcription 
regulatory sequences for proteins highly expressed in the mammary gland cells. 
Preferably, the expression system or construct of this invention also includes a 3' untranslated region 
downstream of the DNA sequence encoding the desired recombinant protein, or the 3' untranslated region of 
the milk protein gene or the milk protein gene with its 3' untranslated region, any of which can be used for 
regulation. This region can increase expression of the transgene. This region apparently stabilizes the RNA 
transcript of the expression system and thus increases the yield of the desired protein. Among the 3' 
untranslated regions useful in this regard are sequences that provide a poly A signal. 
For expression of Factor IX, it is preferred that the 3' untranslated region is not obtained from the native 
human Factor IX gene. Suitable heterologous 3'-untranslated sequences can be derived, for example, from 
the SV40 small t antigen, the casein 3' untranslated region, or other 3' untranslated sequences well known in 
this art. Preferably, the 3' untranslated region is derived from a milk-specific protein, such as the WAP 
protein. The stabilizing effect of this region's poly A transcript is important in stabilizing the mRNA of the 
expression sequence. Ribosome binding sites are also important in increasing the efficiency of expression of 
Factor IX. Likewise, sequences that regulate the post-translational modification of Factor IX are useful in 
the invention. 
In a particularly preferred embodiment, the transgenes of the invention generally consist of WAP milk 
protein regulatory sequences upstream and downstream flanking the Factor IX cDNA/signal peptide 
sequences. A native 5'-WAP regulatory sequence ending in an accessible restriction site immediately 
before/at the ATG codon may be ligated to the restriction sites that occur at the ATG of translatable 
sequences with no linker sequences derived from the chains of human Factor IX. Each of the combined 5'-
regulatory and Factor IX translatable sequences ending in a particular restriction site may then be ligated to 
a corresponding restriction site which occurs at the beginning of the 3'-untranslated region of WAP and 
adjoining WAP 3'-flanking region. This construction motif enables native 5'-regulatory and 3'-untranslated 
region of the milk protein genes to be immediately juxtaposed without intervening sequences. Particular 
restriction sites at the ends of all constructs may be selected in order to facilitate concatenation of constructs 
into a single domain within the animal genome. 
Thus, in accordance with the present invention a DNA molecule that encodes Factor IX is operably linked to 
cis-acting regulatory sequences which allow for efficient expression of Factor IX in milk. The resulting 
chimeric DNA is introduced into a mammalian embryo, where it integrates into the embryonic genome and 
becomes part of the heritable genetic endowment of all the cells, including the germ line cells, of the adult 
which develops from the embryo. The Factor IX which is expressed in the mammary tissue and secreted 
into the milk of a transgenic mammal obtained in this manner displays a surprisingly high percentage of 
active protein, as measured by enzymatic and coagulation-inhibition assays which are conventionally 
employed to detect Factor IX activity, such as ELISAs, chromogenic activity assays and coagulation 
inhibition assays. 
4. Isolation of Factor IX from the Milk of Transgenic Animals 
Obtaining milk from a transgenic animal according to the present invention is accomplished by conventional 
means. See, for example, McBurney et al., J. Lab. Clin. Med. 64:485 (1964); Velander et al., Proc Nat'l 
Acad. Sci. USA 89:12003 (1992). Factor IX, or fragments thereof, can be isolated and purified from milk or 
urine by conventional means without deleteriously affecting activity. A preferred method of isolation from 
milk consists of a combination of anion exchange and immunochromatography, cryoprecipitations, zinc ion-
induced precipitation of either whole milk or milk whey (defatted milk) proteins. See, for example, Bringe 
et al., J. Dairy Res. 56:543 (1989). 
Milk is known to contain a number of proteases that have the potential to degrade foreign proteins. These 
include an alkaline protease with tryptic and chymotryptic activities, a serine protease, a chymotrypsin-like 
enzyme, an aminopeptidase and an acid protease. Clark et al. (1987) above. It may be desirable, therefore, to 
protect newly secreted Factor IX, or fragments thereof, against proteolytic degradation. Such precautions 
include rapid processing of the milk after collection and addition to the milk of well known inhibitors of 
proteolysis, such as are listed in SIGMA CHEMICAL CO. CATALOG (1993 edition) at page 850. 
Thus, in one embodiment, the transgenic mammal of the present invention produces active human Factor 
IX. For instance, in one embodiment wherein said mammal is a pig, such pig secretes from about 100 to 
about 220 .mu.g of active human Factor IX per milliliter milk. In another embodiment, such pig secretes 
from about 100 to about 185 .mu.g of active human Factor IX per milliliter milk, from about 100 to about 
170 .mu.g of active human Factor IX per milliliter of milk, from about 135 to about 220 .mu.g of active 
human Factor IX per milliliter of milk or from about 145 to about 220 .mu.g of active human Factor IX per 
milliliter of milk, as set forth below. 
Factor IX produced from the transgenic mammal according to the invention has a specific activity which is 
at least about 5 to 200 percent greater than the specific activity of human Factor IX isolated from human 
plasma, as determined by an activated partial thromboplastin clotting time assay. In another embodiment, 
the specific activity of Factor IX produced by the transgenic mammal of the invention is at least about 10 to 
100 percent greater, at least about 15 to 50 percent greater or at least about 15 to about 46 percent greater 
than the specific activity of human Factor IX isolated from human plasma. 
In another embodiment, the invention relates to an in vitro culture of mammary gland cells explanted from 
the transgenic mammal of the invention. Such cells are explanted and cultured in vitro, according to 
methods well known to the skilled artisan. See e.g., U.S. Pat. No. 5,580,781. In another embodiment, Factor 
IX is isolated and purified from the in vitro cell culture, according to methods well known to the skilled 
artisan. 
5. Treatment Methods
In another embodiment, the present invention relates to a method of treating hemophilia B using Factor IX 
produced by the transgenic mammal of the invention. Specifically, treatment includes the prevention or 
amelioration of the symptoms of hemophilia B in hemophilia B patients. Symptoms of hemophilia B include 
excessive bleeding upon injury, spontaneous bleeding, especially into weight-bearing joints, soft tissues and 
mucous membranes. Repeated bleeding into joints results in hemarthroses, which causes painful crippling 
arthropathy that necessitates joint replacement. Hematomas in soft tissues may result in "pseudo" tumors 
composed of necrotic coagulated blood. Such blood can obstruct, compress or rupture into adjacent organs 
and can lead to infection. Bleeding into gastrointestinal tract, central nervous system, intracranium or 
airway/retroperitoneal space can lead to death if not detected. This, treatment according to the present 
invention includes the prevention or amelioration of bleeding and the related side effects found in 
hemophilia B patients. This method involves administering to a patient having hemophilia B symptom, a 
hemophilia B symptom preventing or ameliorating amount of Factor IX produced by the transgenic 
mammal of the present invention. Administration may be accomplished by any method known to the skilled 
artisan. For instance, the treatment of the above described symptoms may consist of intravenous 
replacement therapy with Factor IX concentrates. Treatment of major bleeding episodes may be by bolus 
injection of concentrate. However, as described above, tissue damage may remain even after prompt 
detection and treatment. Prophylactic treatment is recommended to prevent pain and debilitation. Upon 
injection, 50% of Factor IX, according to the invention, is immediately bound to vascular endothelial cells 
and/or diffuses into the extravascular space. The remaining 50% has a half life in circulation of 
approximately 24 hours. These infusion kinetics result in the need for injections about once to twice per 
week to maintain minimal therapeutic levels in the plasma. 
Another embodiment of the invention relates to pharmaceutical compositions comprising the Factor IX of 
the present invention. Such pharmaceutical composition preferably is Factor IX produced by the above 
described transgenic animal and a pharmaceutically acceptable carrier. For instance, such pharmaceutical 
composition may be a stable liquid formulation of the Factor IX of the invention that can be administered by 
continuous infusion to provide a constant circulating level of the coagulation factor. 
The Factor IX produced by the transgenic animal of the present invention may be concentrated and sold in 
lyophilized form, according to methods well known to the skilled artisan. For instance, the Factor IX of the 
present invention which has been lyophilized may be reconstituted with sterile water for injection (WFI) and 
delivered in a composition of: 0.01 moles/liter histidine, pH 7.05; 0.066 moles/liter sodium chloride; 3% 
mannitol. In another embodiment, lyophilized Factor IX is reconstituted in sterile WFI and delivered in a 
composition that includes: 0.04 units heparin/unit FIX; 1 milligram dextrose/unit Factor IX. To avoid 
repeated invasive treatments as is found with the current therapies for prophylaxis, stabilities of at least 30 
days at 37.degree. C. and at least 365 days at 4.degree. C. are preferred. The present invention provides 
significant stability over that of these preparations reconstituted. 
This skilled artisan would know of other suitable formulations for the Factor IX of the present invention. 
See, for instance, AlphaNine by Therapeutic Corporation, Los Angeles, Calif., and Bebulin V H, by 
Immuno, Vienna, Austria. Of course, any formulations according to the present invention are highly purified 
and free of viruses, prions, blood-group antibodies, immune complexes and phospholipids. 
Dosages or amounts that prevent or ameliorate the symptoms of hemophilia B are necessarily dictated by 
the clinical picture and severity of the disease. Because there is so much variability between patients and 
their clinical conditions, monitoring of coagulation function is essential in during any therapy using the 
Factor IX of the invention. As a rule, on initial treatment, one unit of Factor IX per kg body weight gives a 
mean rise in Factor IX activity of about 0.5-1%, on continuation therapy, the mean rise is about 1-1.5% 
Examples of dosages for long term prophylaxis of symptoms of hemophilia B are about 18-30 IU/kg 
(1.times.weekly) or about 9-15 IU/kg (2.times.weekly). Dosages also will vary depending upon the purpose 
of the treatment. For instance, where a hemophilia B patient has had surgery, it may be desirable to raise 
Factor IX levels in such patients by 30 to 50% following the week of surgery. For dental extractions, the 
Factor IX levels may need to be raised to 50% immediately prior to the surgery. Mild to moderate 
hemorrhages may be treated with a single administration of the Factor IX of the invention to raise Factor IX 
levels to 20 to 30%. In the even to more serious hemorrhages, it may be desirable to raise Factor IX levels to 
30 to 50% and infusions may be required daily. Again, those of skill in the art would know how to adjust the 
amount and frequency of dosages of the Factor IX of the present invention depending upon the patient and 
the clinical setting. 
In yet another embodiment, the invention relates to a method of treating hemophilia B using Factor IX-
producing cells that are explanted from the transgenic mammal of the present invention. Such mammary 
gland cells express Factor IX in vivo, thereby preventing or ameliorating the symptoms of hemophilia B. 
This method is accomplished by using known techniques for gene therapy. See e.g., Debs, R. Proc. Natl' 
Acad. Sci. (USA) 89: 11277-11281 (1992), Legendre et al., Pharmaceutical Res. 9: 1235-42 (1992). In one 
embodiment, Factor IX-producing cells removed from the transgenic mammal according to the invention 
are cultured in an in vitro culture system prior to transplantation into a human. Such culture systems are well 
known to the skilled artisan. See e.g. U.S. Pat. No. 5,580,781. The cells are treated and then transplanted 
into the patient in a manner so as to avoid rejection by the recipient. Such methods are known to the skilled 
artisan. See, for instance, U.S. Pat. No. 5,573,934, which teaches a method of encapsulating biological 
material for use in vivo. Other techniques known to the skilled artisan involve placing the biological 
material in a chamber of an immunoisolation apparatus and for enhancing the vascular support for the 
implanted material using immunomodulatory agents. See, U.S. Pat. No. 5,569,462. 
The present invention, thus generally described, will be understood more readily by reference to the 
following examples, which are provided by way of illustration and are not intended to be limiting of the 
present invention. 
EXAMPLE 1 
Preparation of a Human Factor IX Expression Vector for Production of Transgenic Pigs 
Generally, the entire murine WAP gene including 2.5 kb of 5' untranslated sequence and 3' untranslated 
regions was cloned by standard methods. See Campbell et al., Nucleic Acids Res. 12:8685 (1984). A cDNA 
fragment encoding human Factor IX was obtained and the 3' untranslated region was deleted. Using 
standard methods, an expression vector was constructed that contained a mouse WAP promoter, isolated as 
a 2.6 kb EcoRI-KpnI fragment immediately 5' to the WAP signal sequence, the human Factor IX cDNA 
sequence lacking a 3' untranslated region, and a 1.6 kb fragment of the 3' untranslated region of the WAP 
gene. A second expression vector contained a 7.2 kb mouse WAP gene (EcoRI-EcoRI) fragment. 
Expression vectors were amplified by bacterial transformation and purified from bacterial cultures using 
standard methods. Routine recombinant DNA techniques can be found, for example, in Sambrook et al., 
MOLECULAR CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold Spring Harbor Press 1989). 
More specifically, a chimeric Factor IX construct was prepared, as follows: 
1. Preparation of a Chimeric Factor IX Construct Production of pWAP4 "cassette vector" 
Regulatory 5' and 3' flanking sequences of the mouse WAP gene were used for mammary specific 
expression. Specifically, a cassette vector containing a mouse WAP promoter, defined as a 2.6. kb EcoRI-
KpnI fragment immediately 5' to the WAP signal sequence and a 1.5 kb fragment of the 3' untranslated 
region of the WAP gene was prepared. These regulatory sequences do not include coding and intragenic 
untranslated sequences (introns) of the WAP gene. 
The vector designated pWAP4 was derived from pWAPPC3 (C. Russell, dissertation "Improvement of 
Expression of Recombinant Human Protein C in the Milk of Transgenic Mammal Using a Novel Transgenic 
Construct," Virginia Technology Institute, Blacksburg, Va. (December 1993)) and was developed as 
follows: Using WAPPC3 as a template, PCR primers WAP3'S2 (which contains a 5'KpnI site and is 
homologous to endogenous WAP right after the stop signal) and WAP3'A1, as shown in Table 1, below, 
were used to produce a segment with KpnI and BamHI sites on either end. This segment was digested with 
KpnI/BamHI and ligated with the vector containing the fragment from KpnI.backslash.BamHI digested 
pWAPPC3. The ligation mixture was used to transform E. coli DH5.alpha. cells by electroportation with 
resultant colonies grown on LB ampicillin plates. Picked colonies were grown up in TB ampicillin broth, 
plasmids isolated and cut with KpnI, BamHI or both and subjected to gel electrophoresis. Sequencing was 
performed using WAP3'A1 primer and judged as being correct. See FIG. 1A. 
Production of Modified (Kpn I) FIX cDNA 
The FIX cDNA (containing Kpn I sites located immediately before the start sequence and after the stop 
sequence) was generated as a PCR fragment. Fragment production protocol is as follows: 100 .mu.l total 
volume containing 200 .mu.M dNTP's, 0.5 .mu.M of each primer (humFIX5'KpnI and humFIX3'KpnI, as 
shown in Table 1), 2.5 units Pfu polymerase and 30 ng of plasmid template (pMCDSFIX obtained from 
Prof. Darryl Stafford, Department of Biology, University of North Carolina, Chapel Hill, N.Car., USA), 
reaction mixture was subjected to 30 cycles of denaturation at 95.degree. C. for 20 sec, annealing at 
50.degree. C. for 1 min and elongation at 75.degree. C. for 5 min 45 sec. After cycling, the reaction mixture 
was subjected to blunting with T4 DNA polymerase for 10 min, EDTA concentration brought up to 25 mM, 
heated to 65.degree. C. for 15 min, and extracted with Phenol: Chloroform (1:1), precipitated with equal 
volumes of 95% ethanol, aspirated, and suspended in H.sub.2 O. 
Ligation, Transformation and Sequencing 
As is shown in FIG. 1B, the plasmid designated pUCFIX containing the modified (Kpn I ends) FIX cDNA 
was produced by digestion of both pUC18 and the modified cDNA with Kpn I (per manufacturers 
instructions, Stratagene, La Jolla, Calif.) purification of digestion products by CHCl.sub.3 : Phenol (1:1) 
extraction, precipitation with equal volumes of 95% ethanol, aspiration and suspension in H.sub.2 O. 
Ligation of plasmid and cDNA was per manufacturers instructions (Stratagene) using 125 ng of Kpn I 
digested pUC18 and 125 ng of Kpn I digested modified cDNA. E. coli JM109 was transformed by 
electroportation using ligation mixture and plated on LB ampicillin plates. Selected colonies were grown up 
in TB ampicillin broth. Plasmid preparations from these colonies were analyzed by restriction enzyme 
digestion (Kpn I) and gel electrophoresis. The entire sense strand of the cDNA was sequenced and found to 
be correct as compared with FIXA sequences located in Genebank. 
Introduction of FIX CDNA into pWAP4 "cassette vector" to Produce pWAPFIX 
As shown in FIG. 1C, both pWAP4 and pUCFIX were digested with Kpn I in separate reactions, subjected 
to gel electrophoresis and the appropriate plasmid fragments removed from the gel and ligated. E. coli 
JM109 was transformed by electroportation using ligation mixture and plated on LB ampicillin plates. 
Selected colonies were grown up in TB ampicillin broth. Plasmid preparations from these colonies were 
analyzed by restriction enzyme digestion (Kpn I) then gel to electrophoresis. Clones positive for the insert 
were subjected to PCR analysis using primers FIXS1 and WAP3'A1 to determine the correct orientation of 
the insert. 
Production of pUCWAPFIX 
As shown in FIG. 1D, the insert containing WAP promoter, cDNA and 3'WAP UTR was released from 
pWAPFIX by EcoR I digestion, subjected to gel electrophoresis, removed from the gel and purified. This 
fragment was ligated with Kpn I digested pUC18 and the reaction mixture used to transform E.coli JM109 
by electroportation. After electroportation, cells were plated on LB ampicillin plates with picked colonies 
grown in TB ampicillin broth. Plasmids from picked colonies were purified and subjected to EcoRI enzyme 
digestion and electrophoresis. After insert confirmation, large scale purification was undertaken, according 
to methods well known to the skilled artisan. 
2. Preparation of Factor IX-Encoding DNA for Microinjection 
Chimeric constructs containing either the 7.2 kb mouse WAP gene, or containing the WAP promoter, 
human Factor IX gene and 3' WAP sequence were excised from pUCWAPFIX by EcoRI restriction digest 
and purified for microinjection using low melting point agarose electrophoresis. The DNA: agarose band 
was cut from the gel slab. The agarose band was then treated with agarase to degrade and remove agarose 
contamination. 
After digestion, the solution containing the cDNA was brought to 10 mM Mg2+, 20 mM EDTA and 0.1% 
SDS and then extracted with phenol/chloroform. DNA was precipitated from the aqueous layer with 2.5 
volumes of ethanol in the presence of 0.3 M sodium acetate ate -20 degrees centigrade overnight. After 
centrifugation, the pellet was washed with 70% ethanol, dried, and each of the constructs was resuspended 
and dissolved in Brinsters microinjection buffer to a concentration of 1.4 or 7 .mu.g/ml (for mice), 14 
.mu.g/ml (for pigs). 
According to another protocol, extracted DNA was purified by HPLC, as follows. After cleaving a chimeric 
gene from its vector, the solution was brought to 10 mM magnesium, 20 mM EDTA and 0.1% SDS and 
then extracted with phenol/chloroform. DNA was precipitated from the aqueous layer with 2.5 volumes of 
ethanol in the presence of 0.3 M sodium acetate at -20.degree. C. overnight. After centrifugation, the pellet 
was washed with 70% ethanol, dried, and resuspended in sterile distilled water. 
The digested DNA was precipitated with isopropanol and then dissolved in TE buffer at 0.3 .mu.g/ml. 
Fragments were purified by HPLC using a Waters GEN FAX PAC HPLC column. The column was run 
isocratically using a buffer consisting of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, and 0.63 M NaCl. 
About 15 .mu.g of digested DNA was loaded on the column at a time. DNA samples from all of the 
chromatographic runs were then pooled, reprecipitated, and run through the column a second time. 
DNA concentrations were determined by agarose gel electrophoresis by staining with ethidium bromide and 
comparing the fluorescent intensity of an aliquot of the DNA with the intensity of standards. Samples were 
then adjusted to 10 .mu.g/ml and stored at -20.degree. C., prior to microinjection. 
EXAMPLE 2 
Production of Transgenic Pigs That Express the Human Factor IX Gene 
Pig embryos were recovered from the oviduct, and were placed into a 1.5 ml microfuge tube containing 
approximately 0.5 ml embryo transfer media (Beltsville Embryo Culture Medium). Embryos were 
centrifuged for 12 minutes at 16,000.times.g RCF (13,450 RPM) in a microcentrifuge (Hermle, model 
Z231). The embryos were then removed from the microfuge tube with a drawn and polished Pasteur pipette 
and placed into a 35 mm petri dish for examination. If the cytoplasm was still opaque with lipid such that 
pronuclei were not visible, the embryos were centrifuged again for 15 minutes. Embryos were then placed 
into a microdrop of media (approximately 100 .mu.l) in the center of the lid of a 100 mm petri dish, and 
silicone oil was used to cover the microdrop and fill the lid to prevent media from evaporating. The petri 
dish lid containing the embryos was set onto an inverted microscope (Carl Zeiss) equipped with both a 
heated stage and Hoffman Modulation Contrast optics (200.times.final magnification). A finely drawn 
(Kopf Vertical Pipette Puller, model 720) and polished (Narishige microforge, model MF-35) micropipette 
was used to stabilize the embryos while about 1-2 picoliters of HPLC-purified DNA solution containing 
approximately 200-500 copies of a mixture of the two chimeric constructs was delivered into the male 
pronucleus with another finely drawn micropipette. Embryos surviving the microinjection process as judged 
by morphological observation were loaded into a polypropylene tube (2 mm ID) for transfer into the 
recipient pig. 
EXAMPLEe 3 
Production of pUCWAP6 "Cassette Vector" and Plasmid pUCWAP6FIX 
Production of pUCWAP6 "cassette vector" 
Generally, the entire murine WAP gene was cloned by standard methods, as described above in Example 1, 
and regulatory 5' and 3' flanking sequences of the mouse WAP gene were used for mammary specific 
expression. Specifically, a cassette vector containing a mouse WAP promoter, defined as a 4.1 kb NotI-
KpnI fragment immediately 5' to the WAP signal sequence and a 1.6 kb fragment of the 3' untranslated 
region of the WAP gene was prepared. These regulatory sequences do not include coding and intragenic 
untranslated sequences (introns) of the WAP gene. 
The vector designated pUCWAP6 was derived from genetic elements from the following plasmids as 
starting material: pUC18, pWAP4 and p227.6, which were provided by the American Red Cross. The 
development of pUCWAP6 is as follows: The pUC18 vector was cut with the enzymes EcoRI and Hind III 
to remove the multiple cloning site of the vector, blunted with exonuclease and ligated with NotI linkers. 
The linearized plasmid was then cut with NotI and ligated. Ligation mixture was used to transform E. coli 
DH5.alpha. cells on LB ampicillin plates, picked colonies were grown in TB ampicillin broth, plasmids 
were isolated and cut with NotI then subjected to gel electrophoresis. Plasmid was judged to be correct and 
designated as pUCNotI (See FIG. 3A). The vector pWAP4 was cut with EcoRI and the fragment containing 
the WAP 5' 2.6 kbp and 3' genetic elements were separated by gel electrophoresis and purified. The ends of 
the fragment were modified by blunting with exonuclease and NotI linkers were ligated on. The fragment 
was cut with NotI and ligated into the NotI restriction site of pUCNotI then used to transform E. coli 
DH5.alpha. cells on ampicillin plates picked colonies were grown in TB ampicillin broth. Isolated plasmid 
was verified to be correct by NotI digestion with the plasmid being designated pUCWAP5. The pUC WAPS 
plasmid was subjected to KpnI digestion and a partial NotI digestion producing a fragment that contained 
the pUCNotI vector sequence flanked by the mWAP 3'UTR (See FIG. 3B). This fragment was ligated with 
the 4.1 kb 5' WAP promoter produced from digestion of p227.6 with NotI, KpnI and Hind III. The ligation 
mixture was then used to transform E.coli JM109 cells that were grown on LB ampicillin plates picked 
colonies were grown in TB ampicillin broth, plasmids isolated were cut with Not I, and NotI/KpnI and 
judged to be correct. The plasmid was then designated pUCWAP6 (See FIG. 3C). 
Production of pUCWAP6FIX 
As shown in FIG. 4, the plasmid pUCWAP6FIX was produced by digestion of pUCWAPFIX with KpnI and 
isolating the FIX cDNA by gel electrophoresis. This fragment was inserted into the KpnI site of pUCWAPG 
after KpnI digestion and both fragments were then subjected to ligation. The ligation mixture was then used 
to transform E. coli JM109 cells that were then plated on LB ampicillin plates. Picked colonies were grown 
in TB ampicillin broth and plasmids were isolated. Isolated plasmids were digested with NsiI to verify 
orientation of the cDNA insert. Plasmids that contained the insert in the correct orientation were designated 
pUCWAP6FIX. After insert confirmation, large scale purification was undertaken, according to methods 
well known in the art. DNA was prepared for microinjection as described above. 
EXAMPLE 4 
Production of Transgenic Mice That Express the Human Factor IX Gene 
Transgenic mice were produced essentially as described by Hogan et al., Manipulating the Mouse Embryo, 
Cold Spring Harbor Press, (1986), which is hereby incorporated by reference. That is, glass needles for 
micro-injection were prepared using a micropipet puller and microforge. Injections were performed using a 
Nikon microscope having Hoffman Modulation Contrast optics, with Narashigi micromanipulators and a 
pico-injector driven by N2 (Narashigi). 
Fertilized mouse embryos were surgically removed from oviducts of superovulated female CD-1 mice and 
placed into M2 medium. Cumulus cells were removed from the embryos with hyaluronidase at 300 
.mu.g/ml. The embryos were then rinsed in new M2 medium, and transferred into M15 medium for storage 
at 37 degrees centigrade prior to injection. 
Stock solutions containing about 1.4 .mu.g/ml of the above described DNA were prepared and 
microinjected into the pronuclei of 1 cell mouse embryos. In addition, stock solutions containing about 7 
.mu.g/ml total DNA were prepared and microinjected into the pronuclei of mouse embryos. 
After injecting the DNA solution into the male pronucleus, embryos were implanted into avertin-
anesthesized CD-1 recipient females made pseudo-pregnant by mating with vasectomized males. About 25-
30 microinjected mouse embryos per recipient were transferred into pseudopregnant females. Embryos were 
allowed to come to term and the newborn mice were analyzed for the presence of the transgene by PCR 
using the primers FIXS1 and FIXA1 described in Table 1, below. 
EXAMPLE 5 
Preparation of DNA from Transgenic Animals 
DNA can be prepared from tissue of a transgenic animal of any species by the method exemplified below 
for mice. Marmur., J. Mol. Biol. 3: 208 (1961), incorporated herein by reference. 
A 5 mm piece of mouse tail was removed from young, potentially transgenic mice at weaning (3 weeks) 
age, and frozen in liquid nitrogen. To the frozen tissue was added 840 .mu.l of Lysing Solution (8 mM 
EDTA-0.8% 2-mercaptoethanol-80 .mu.g/ml Proteinase K-1 M sodium chlorate in 40 mM TRIS buffer) pH 
8.0 and 120 mM NaCl, and the mixture incubated at 50 degrees centigrade. The mixture was then extracted 
with 250 .mu.l of phenol/chloroform/isoamyl alcohol (25:24:1) for 10-15 seconds, then centrifuged for 10 
minutes. The supernatant fluid (about 830 .mu.l) was removed to a fresh tube, and a DNA clot produced by 
vortexing the solution with 0.6 vols. of isopropanol. The mother liquor was decanted, and the DNA clot 
rinsed twice with 80% ethanol. The DNA clot was isolated by 5 minutes or centrifugation, aspiration of the 
supernatant fluid, and air drying of the clot with a stream of air for 10 minutes. 
The DNA clot was dissolved in 250 .mu.l of the TE buffer (10 mM Tris. HCl, pH 7.0--1 mM EDTA, and 
the solution treated with 10 .mu.l of RNase (1 mg/ml RNase A and 4,0000 units/ml RNAse T1) for 1 hour at 
37 degrees centigrade. This mixture was shaken with 50 .mu.l of a 24:1 (v/v) solution of chloroform-
isoamyl alcohol for 5-10 seconds, centrifuged, and the supernatant fluid transferred to a fresh tube. 
The recovered supernatant fluid above was mixed sequentially with 25 .mu.l of 3M sodium acetate and 0.5 
ml of 95% ethanol. The supernatant fluid above was mixed sequentially with 25 .mu.l of 3M sodium acetate 
and 0.5 ml of 95% ethanol. The supernatant fluid was decanted from the precipitated DNA, and the 
precipitate washed with 80% ethanol. The purified DNA was isolated by centrifugation, air dried, then 
dissolved in 150 .mu.l of TE. 
Essentially the same technique was used to prepare DNA from pigs, and the same or similar techniques can 
be used to prepare DNA from other animals. Such DNA can be analyzed to determine whether transgenic 
animals carried recombinant structures. 
EXAMPLE 6 
Analysis of DNA Derived From Tissue 
To determine whether test animals carried the recombinant constructs, tissue samples were removed from 
transgenic animals and treated with proteinase K and SDS at 37.degree. C. overnight. The mixture was then 
incubated with DNase-free RNase at 37.degree. C. for 1-2 hours. DNA was precipitated from the mixture 
with sodium acetate and ethanol at -20.degree. C. overnight, collected by centrifugation, washed in 70% 
ethanol and dried. The dried DNA pellet was used directly for polymerase chain reaction (PCR) In some 
cases, the mixture was extracted extensively with phenol/chloroform prior to ethanol precipitation. 
Oligonucleotide pairs were used to prime polymerase chain reactions that detected the presence of the WAP 
gene or the Factor IX gene in the transgenic animals. See Table 1, below. Reactions were performed using 
an annealing temperature of 58.degree. C., a denaturation temperature of 94.degree. C., and an extension 
temperature of 72.degree. C., using 100 ng of oligo primers and 50 ng of (genomic) template DNA per 
reaction, and cycling through the temperatures 40 times using an automatic temperature cycler (M.J. 
Research). PCR reactions were analyzed by running 20% of the reaction products on agarose gels and 
identifying fragment sizes by comparison with marker DNA fragments. 
Two founder transgenic pigs (one male and one female) contained a 2.6 kb mouse WAP promoter-Factor IX 
cDNA-1.6 kb WAP gene 3-'end construct that had been coinjected with the 7.2 kb mouse WAP gene 
(EcoRI-EcoRI) fragment. As shown in Table 2, the male, 57-7, did not transmit the transgene. In contrast, 
founder 58-1 has produced one female offspring having the Factor IX cDNA transgene. Founder 58-1 has 
produced six additional offspring, three females and three males, from her second litter. The three females 
were not transgenic. Two of the males from the second litter tested positive for the Factor IX transgene. 
Table 1 
Primer Sequences 
humFIX5'KpnI(SEQ ID NO:1) 5'gcta.backslash.ggtacc.backslash.atgcagcgcg 
humFIX3'KpnI(SEQ ID NO:2) 5'gtca.backslash.ggtacc.backslash.ttaagtgagct
FIXS1(SEQ ID NO:3) 5'ggataacatcactcaaagcac 
WAP3'A1(SEQ ID NO:4) 5'tagcagcagattgaaagcattatg 
FIXA1(SEQ ID NO:5) 5'gtgaactttgtagatc 
                             TABLE 2
           Transgenic Pigs Containing Recombinant Human
Factor IX DNA
        Pig ID    Construct   Sex         Comments
        57-7      WAP/FIX     Male        Founder, PCR* positive
                                          for WAP and FIX
        58-1      WAP/FIX     Female      Founder, PCR positive
                                      for WAP and FIX
        63-1      WAP/FIX     Female      G.sup.1 from 58-1, positive
                                          for WAP and FIX
        63-2      WAP/FIX     Female      G.sup.1 from 58-1, positive
                                      for WAP and FIX (dead)
        litter    WAP/FIX     3 Female,   2 transgenic males
        #10                   3 Male
        to 58-
        1
    WAP: Whey acid protein; FIX: Factor IX;
    *Detection of human Factor IX transgene carried out by the PCR method.
EXAMPLE 7 
Expression of Human Factor IX in the Milk of Transgenic Pigs 
Daily expression levels of recombinant human Factor IX in the milk of transgenic pig 58-1 were determined 
as follows. Lactating sows were injected intramuscularly with 30-60 IU of oxytocin (Vedco Inc., St. Joseph, 
Mo.) to stimulate milk let-down. Letdown occurred two to five minutes after injection. Pigs were milked by 
hand during the course of this study. Immediately after collection the milk was diluted 1:1 with 200 mM 
EDTA, pH 7.0 to solubilize the caseins and then frozen. Small aliquots (about one milliliter) of the 
milk/EDTA mixture were taken and centrifuged for approximately 30 minutes at 16000.times.g at 4.degree. 
C. The fat layer was separated from the diluted whey fraction, and the diluted whey fraction was used for all 
further assays. In this study, all concentration values reported for milk were obtained from diluted whey 
samples that were multiplied by a factor of 1.9 to account for dilution with EDTA and subsequent removal 
of milk fat. 
Amounts of Factor IX in milk were measured by polyclonal ELISA. Briefly, Immulon II microtiter plates 
(Fisher Scientific, Pittsburgh) were coated overnight with 100 .mu.l/well of 1:1000 rabbit anti-human Factor 
IX (Dako) in 0.1 M NaHCO.sub.3, 0.1 M NaCl, pH 9.6 at 4.degree. C. The wells were washed with TBS-
Tween (TBST, 25 mM Tris, 50 mM NaCl, 0.2% Tween 20, pH 7.2), and then blocked for 30 minutes with 
TBS/0.1% BSA at room temperature. Samples and human Factor IX standard (a gift from the American Red 
Cross) in the TBS-BSA dilution buffer were added in triplicate to the wells (100 .mu.l/well) and incubated 
at 37.degree. C. for 30 minutes. The wells were then washed and blocked for another 10 minutes at room 
temperature. Goat anti-human Factor IX (American Diagnostica, Greenwich, Conn.), 1:1000 in TBS-BSA, 
was then incubated in the wells for 30 minutes at 37.degree. C., followed by anti-goat IgG/HRP (Sigma, St. 
Louis). Bound chromophore was detected with OPD substrate (Abbott, Chicago) at 490 nm using an EL308 
Bio-Tek Microplate reader. 
As shown in Table 3, daily expression levels of 100-220 .mu.g/ml milk were maintained throughout the 10 
day lactation. 
                             TABLE 3
                 Recombinant Factor IX Levels
         in Milk of Transgenic Pig 58-1, First Lactation
                                           rhFIX
                   Day of              Level.sup.2
                  Lactation             [.mu.g/ml]
                    3                 160 .+-. 26
                      4                 145 .+-. 20
                      5                 100 .+-. 25
                      6                 135 .+-. 15
                      7                 220 .+-. 30
                      9                 170 .+-. 35
                     10                 185 .+-. 50
    .sup.2 Recombinant human Factor IX (rhFIX) levels were determined by ELISA
     on daily samples of EDTA-diluted whey.
EXAMPLE 8 
Western Analysis of Human Factor IX Produced by Transgenic Pigs 
Recombinant human Factor IX also was examined using Western analysis. Daily samples of EDTA-diluted 
whey from 58-1 were electrophoresed on 8-16% SDS gels (Novex, San Diego). Approximately 125 ng of 
recombinant human Factor IX (as determined by polyclonal ELISA) and human Factor IX standard 
(American Red Cross), were loaded in each lane. A total of 25 .mu.g of total protein from a pool of non-
transgenic (NTG) whey was loaded on the gels. After electrophoresis, proteins were transferred overnight to 
PVDF membranes (Bio Rad). The membranes were washed for 30 minutes in TBST, blocked with 
TBS/0.05% Tween 20/0.5% Casein (TBST-Casein). The membranes were developed with rabbit anti-Factor 
IX (Dako) (1:1000 in TBST- Casein for 45 minutes at 37.degree. C.), followed by anti-rabbit IgG/HRP 
(Sigma) (1:1000 in TBST-Casein for 45 minutes at 37.degree. C.), and the DAB metal enhanced staining 
(Pierce). Molecular weight markers were purchased from Bio Rad. 
Western analyses revealed the presence of three sub-populations of recombinant human Factor IX: the 
major population migrated at a M.sub.r of about 60-65 kDa, which is a slightly lower M.sub.r than human 
Factor IX, and minor sub-populations migrated at about 40-45 kDa, and at about 25 kDa. Plasma human 
Factor IX also possessed a subpopulation at about 45-50 kDa. 
In yet another study, whole milk from transgenic pig 58-1 was diluted 1:1 with 200 mM EDTA, pH 7.0 to 
dissociate casein micelles. Milk was skimmed of fat by centrifugation at 4000.times.g for 30 min, at 
2.degree. C. 100 .mu.gs of milk protein were loaded per lane of a 4%/10% SDS-PAGE gel and resolved at 
15 mA/hr for one hour and 30 mA/hr for 2 hours. Proteins were transferred onto nitrocellulose paper 
(Amersham), at 24 V/h, 4.degree. C. and western blotted to detect rFIX in milk, using an HRP-conjugated 
goat anti-FIX antibody (Affinity Biologicals) at 0.9 .mu.g/ml concentration. The results of this study are set 
forth in FIG. 1, wherein lanes 1-8 represent milk from day 3, 4, 5, 6, 7, 9, 10, 11 of lactation; lane 9, purified 
recombinant FIX, 1.0 .mu.g; and lane 10, human FIX purified from plasma, 0.5 .mu.g. The positions of 
broad range molecular weight markers (BioRad) are indicated on the left. 
EXAMPLE 9 
Purification of Human Factor IX from Milk of Transgenic Pigs 
Recombinant human Factor IX was purified from a pool of the first lactation from the milk of 58-1 using 
ion exchange chromatography followed by metal-dependent immunoaffinity chromatography (MAb 1H5). 
In these studies, all columns and buffers were kept at 4.degree. C. A pool of daily EDTA-expanded whey 
samples was diluted to OD 280 nm of 5.0 with TBS, pH 7.2, then loaded at 1 cm/min on DEAE FF 
Sepharose. The column was washed with TBS, pH 7.2, and then eluted with 0.25 M NaCl in TBS. This 
fraction was diluted 1:1 with 40 mM MgCl.sub.2 in TBS to a final concentration of 20 mM MgCl.sub.2 and 
loaded on a 1H5 MAb column. The column was washed with TBS containing 20 mM MgCl.sub.2, and the 
product was eluted with 20 mM citrate, 0.15 M NaCl, pH 6.8. The product was dialyzed overnight against 
10 mM imidazole, pH 7.2. 
The yields from the anion exchange and immunoaffinity steps were quantitative, and no recombinant human 
Factor IX was detected in the flow-through chromatographic fractions by polyclonal ELISA. This two-step 
chromatographic procedure isolated the recombinant human Factor IX to about 80-90% purity. 
EXAMPLE 10 
The Biological Activity of Purified Recombinant Human Factor IX 
The biological activity of the purified recombinant human Factor IX from 58-1 was measured using a one-
stage activated partial thromboplastin clotting time assay (APTT) clotting assay following a protocol given 
by the American Red Cross Plasma Derivatives Laboratory (Procedure for Factor IX Coagulation Assay, 
March 1992). Briefly, each well of a plastic Coag-a-mate tray received 90 .mu.l of Factor IX-deficient 
plasma plus 10 .mu.l of a Factor IX standard or sample, diluted with Tris/saline/BSA. The tray was then 
placed on an automated analyzer (APTT mode, 240 second activation). The run was started, which 
automatically performed the addition of 100 .mu.l of APTT reagent and 100 .mu.l of 0.025 M CaCl.sub.2. 
Data obtained using a standard Factor IX preparation were fitted to the equation y-ax+b where y=clotting 
time and x=Factor IX, which was then used to determine the amount of Factor IX in a sample. The 
Standards of normal plasma reference pool (Sigma) and human Factor IX (American Red Cross Plasma 
Derivatives Laboratory) were used in the assay. Duplicates of 58-1 recombinant human Factor IX, human 
Factor IX, and normal plasma reference pool samples were run at each dilution. 
As shown in Table 4, the immunopurified recombinant human Factor IX had a specific activity of 337 
U/mg, which is comparable to the immunopurified human Factor IX from plasma which had a specific 
activity of 230 U/mg, and the normal plasma reference pool activity of 250 U/mg. 
                             TABLE 4
         Specific Activity of Recombinant Human Factor IX
            Purified from the Milk of a Transgenic Pig
                    Slope                    Activity  Specific
    Sample   Slope  Ratio      Equation        (%)    Activity
     NPRP    0.094    1.0 y = 0.094 x - 3.7   100%    250 U/mg
     hFIX    0.086    0.92 y = 0.086 x - 3.6    92%    230 U/mg
     rhFIX   0.127    1.35 y = 0.127 x - 3.4   135%    337 U/mg
    NPRP: normal plasma reference pool
    hFIX: human Factor IX standard
    rhFIX: Factor IX isolated from the transgenic pig
Although the foregoing refers to particular preferred embodiments, it will be understood that the present 
invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may 
be made to the disclosed embodiments and that such modifications are intended to be within the scope of the 
present invention, which is defined by the following claims. 
All publications and patent applications mentioned in this specification are indicative of the level of skill of 
those in the art to which the invention pertains. All publications and patent applications are herein 
incorporated by reference to the same extent as if each individual publication or patent application were 
specifically and individually indicated to be incorporated by reference in its entirety. 
* * * *
